olanzapine

Trade name: zyprexa

Small moleculeapproved

Approved

Sep 30, 1996

Olanzapine is a novel antipsychotic agent marketed by Lilly & Co. It has a pleotrophic pharmacology and affects dopaminergic, serotonergic, muscarinic and adrenergic activities. Olanzapine is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression) in adults and children who are at least 13 years old. Olanzapine is sometimes used together with other antipsychotic medications or antidepressants. The mechanism of action of olanzapine, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug’s efficacy in schizophrenia is mediated through a combination of dopamine and serotonin type 2 (5HT2) antagonism. The mechanism of action of olanzapine in the treatment of acute manic or mixed episodes associated with bipolar I disorder is unknown. Olanzapine treatment led to rapid phosphorylation of kinases from all three pathways in PC12 cells. Phosphorylation of Akt was blocked with selective inhibitors (wortmannin and LY294002), which implicates phosphoinositide 3-kinase (PI3K) in the signaling cascade. Short-term mitogenic effects of olanzapine were abolished with a selective inhibitor of Akt, but not by inhibition of the ERK pathway. Olanzapine is metabolized by the cytochrome P450 system; principally by isozyme 1A2 and to a lesser extent by 2D6. By these mechanisms more than 40% of the oral dose, on average, is removed by the hepatic first-pass effect. Drugs or agents that increase the activity of CYP1A2, notably tobacco smoke, may significantly increase hepatic first-pass clearance of Olanzapine; conversely, drugs which inhibit 1A2 activity (examples: Ciprofloxacin, Fluvoxamine) may reduce Olanzapine clearance. The most common side effects appear to be somnolence and weight gain. About 11% of patients gain weight -especially if on a high starting dose and if they were underweight pre-treatment. Sexual dysfunction is a problem for many patients, although sexual dysfunction in schizophrneia does not appear to be primarily attributable to drugs. — NCATS

Clinical trial activity

399 trials · 272 clinical orgs · 43 marketing orgs

Phase 1
47
Phase 2
175
Phase 3
122
Phase 4
123

Earliest trial started Sep 1, 1992 (NCT00000373)

Timeline

1990s

  1. Sep 30, 1996

    Eli Lilly — Earliest FDA Approval

  2. Sep 30, 1996

    Eli Lilly — NDA Organization

  3. Sep 30, 1996

    CheplaPharm — Marketing Organization

  4. Jan 1, 1998

    Earliest Phase 3 Sponsor(trial)

  5. Jan 1, 1999

    Earliest Phase 1 Sponsor(trial)

2000s

  1. Jan 1, 2000

    Earliest Phase 2 Sponsor(trial)

  2. Sep 29, 2006

    Roxane Laboratories — Marketing Organization

  3. Sep 29, 2006

    Boehringer Ingelheim — Marketing Organization

2010s

  1. Oct 24, 2011

    Strides Pharma Science — Marketing Organization

  2. Oct 24, 2011

    Apotex — Marketing Organization

  3. Oct 24, 2011

    Dr. Reddy's Laboratories — Marketing Organization

  4. Oct 24, 2011

    Par Pharmaceuticals — Marketing Organization

  5. Oct 24, 2011

    Sandoz — Marketing Organization

  6. Oct 24, 2011

    Teva — Marketing Organization

  7. Oct 24, 2011

    Novartis — Marketing Organization

  8. Jan 30, 2012

    Barr Laboratories — Marketing Organization

  9. Feb 28, 2012

    Sun Pharmaceuticals — Marketing Organization

  10. Mar 20, 2012

    Sankyo — Marketing Organization

  11. Mar 20, 2012

    Lutipold — Marketing Organization

  12. Mar 20, 2012

    Daiichi Sankyo — Marketing Organization

  13. Apr 23, 2012

    Orbion Pharms — Marketing Organization

  14. Apr 23, 2012

    Aurobindo Pharma — Marketing Organization

  15. Apr 23, 2012

    Natco Pharma — Marketing Organization

  16. Apr 23, 2012

    Mylan — Marketing Organization

  17. Apr 23, 2012

    Orchid Pharma — Marketing Organization

  18. Apr 23, 2012

    Torrent Pharmaceuticals Limited — Marketing Organization

  19. Sep 12, 2012

    Jubilant Innovation Ltd. — Marketing Organization

  20. Nov 2, 2012

    Endo Pharmaceuticals — Marketing Organization

  21. Nov 16, 2012

    Epic Pharma Llc — Marketing Organization

  22. Aug 15, 2014

    Macleods Pharmaceuticals, Ltd — Marketing Organization

  23. Aug 15, 2014

    Neogen — Marketing Organization

  24. Apr 29, 2015

    Ivax — Marketing Organization

  25. Oct 20, 2015

    Alkem Labs Ltd — Marketing Organization

  26. Jan 27, 2016

    Qilu Pharmaceutical Co., Ltd. — Marketing Organization

  27. Mar 15, 2016

    Chartwell Pharmaceuticals — Marketing Organization

  28. Mar 15, 2016

    Invagen Pharms — Marketing Organization

  29. Aug 30, 2016

    Ajanta Pharma Ltd — Marketing Organization

  30. Jun 16, 2017

    Hikma — Marketing Organization

  31. Jul 17, 2018

    Zydus Discovery DMCC — Marketing Organization

  32. Sep 24, 2018

    Jiangsu Hansoh Pharmaceutical Co., Ltd. — Marketing Organization

  33. Nov 19, 2018

    Sunshine Lake Pharma Co., Ltd. — Marketing Organization

2020s

  1. Jul 31, 2020

    Indoco Remedies — Marketing Organization

  2. Oct 22, 2020

    Eugia Pharma — Marketing Organization

  3. Dec 31, 2020

    Zhejiang Hisun Pharmaceutical Co. Ltd. — Marketing Organization

  4. May 28, 2021

    Alkermes — NDA Secondary Org

  5. Feb 24, 2023

    Cadila Healthcare — Marketing Organization

  6. Mar 22, 2023

    Aspiro — Marketing Organization

Indications

Studied for

Mechanism of action

Combination products

Approval history

  • approvedSep 30, 1996

Chemistry & pharmacology

Loading structure…

SMILES

Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1.O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O
Mol. weight
718.83 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno(2,3-b)(1,5)benzodiazepine
  • 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno[2,3-b][1,5]benzodiazepine
  • 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno[2,3-b][1,5]benzodiazepine
  • arkolamyl
  • ly-170052
  • ly 170053
  • ly 170053
  • ly-170053
  • ly-170053
  • ly-170053
  • olanzapin
  • olanzapin
  • olanzapina
  • olanzapina
  • olanzapine
  • olanzapine
  • olanzapine
  • olanzapine
  • olanzapine
  • olanzapine
  • olanzapine
  • olanzapine
  • olanzapine
  • olanzapine
  • olanzapine
  • olanzapine
  • olanzapine embonate
  • olanzapine hydrochloride
  • olanzapine pamoate
  • olanzapine pamoate
  • olanzapine pamoate
  • olanzapine pamoate
  • olanzapine pamoate
  • olanzapine pamoate
  • olanzapine pamoate
  • olanzapine pamoate
  • olanzapine pamoate monohydrate
  • olanzapinum
  • olanzapinum
  • zalasta
  • zalasta
  • zolafren
  • zyprexa
  • zyprexa
  • zyprexa
  • zyprexa
  • zyprexa
  • zyprexa
  • zyprexa relprevv
  • zyprexa relprevv
  • zyprexa zydis
  • zyprexa zydis

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06995508Phase 2Nov 15, 2025State University of New York, Buffalo
NCT07246187Phase 3Nov 6, 2025Mercy Bon Secours Saint Vincent Medical Center
NCT07208305Phase 3Sep 30, 2025Qinghai University
NCT07035821Phase 3Jul 1, 2025Jiao Tong University
NCT06850454Phase 3Jan 10, 2025Mahidol University
NCT06554613Phase 2Dec 1, 2024Nanchang University
NCT06588413Phase 3Oct 31, 2024Augusta University
NCT06251635N/AJun 3, 2024University of Toronto
NCT06500234Phase 3Jun 1, 2024Qingdao Central Hospital
NCT06331520Phase 3May 1, 2024Fudan University
NCT06200181Phase 3Apr 2, 2024University of Texas at Houston
NCT06253546Phase 1Mar 28, 2024Teva
NCT06319170Phase 1Mar 28, 2024Teva
NCT06338683Phase 3Mar 20, 2024Qinghai Red Cross Hospital
NCT06315283Phase 1Mar 20, 2024Teva
NCT05705492Phase 2Jan 31, 2024National Cancer Institute (NCI), OHSU Knight Cancer Institute, Oregon Health and Science University
NCT06517199Phase 3Jan 22, 2024Mahidol University
NCT05964647Phase 1Dec 1, 2023University of Basel
NCT06600477Phase 1Oct 16, 2023Neurelis, Inc.
NCT06107803Phase 1Oct 13, 2023Minerva Neurosciences
Showing 20 of 399 trials
Page 1 / 20

Organizations

Research & Development (272)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Eli LillyFor profit785551998
National Institute of Mental Health (NIMH)Government28551992
Johnson and JohnsonFor profit171742004
MerckFor profit171732003
PfizerFor profit15852000
University of TorontoAcademic/Hospital131052002
Janssen Pharmaceutica NVFor profit11032000
AlkermesFor profit9932013
Department of Veteran AffairsGovernment8431998
University of North Carolina at Chapel HillAcademic/Hospital8442000
Washington University in St. LouisAcademic/Hospital8732000
Columbia UniversityAcademic/Hospital7442001
LundbeckFor profit7622006
OtsukaFor profit7522000
Bristol-Myers SquibbFor profit6122000
National Cancer Institute (NCI)Government6332008
Northwell HealthAcademic/Hospital6621998
Peking UniversityAcademic/Hospital6522008
Central South UniversityAcademic/Hospital5432005
Government of TaiwanGovernment5112000
272 organizations
Page 1 / 14

Marketing (55)

OrganizationOrg typeRelationshipDate
Ajanta Pharma LtdFor profitMKTGAug 30, 2016
Alkem Labs LtdFor profitMKTGOct 20, 2015
AlkermesFor profitNDA2May 28, 2021
ApotexFor profitMKTGOct 24, 2011
AspiroFor profitMKTGMar 22, 2023
Aurobindo PharmaFor profitMKTGApr 23, 2012
Barr LaboratoriesFor profitMKTGJan 30, 2012
Boehringer IngelheimFor profitMKTGSep 29, 2006
Cadila HealthcareFor profitMKTGFeb 24, 2023
Chartwell PharmaceuticalsFor profitMKTGMar 15, 2016
CheplaPharmFor profitMKTGSep 30, 1996
Daiichi SankyoFor profitMKTGMar 20, 2012
Dr. Reddy's LaboratoriesFor profitMKTGOct 24, 2011
Eli LillyFor profitSYNDec 11, 2009
Eli LillyFor profitIND
Eli LillyFor profitNDASep 30, 1996
Endo PharmaceuticalsFor profitMKTGNov 2, 2012
Epic Pharma LlcFor profitMKTGNov 16, 2012
Epic Pharma LlcFor profitSYNNov 16, 2012
Eugia PharmaFor profitMKTGOct 22, 2020
HikmaFor profitSYNJun 16, 2017
HikmaFor profitMKTGJun 16, 2017
Indoco RemediesFor profitMKTGJul 31, 2020
Indoco RemediesFor profitSYNJul 31, 2020
Invagen PharmsFor profitMKTGMar 15, 2016
IvaxFor profitMKTGApr 29, 2015
Jiangsu Hansoh Pharmaceutical Co., Ltd.For profitMKTGSep 24, 2018
Jubilant Innovation Ltd.For profitMKTGSep 12, 2012
LutipoldFor profitMKTGMar 20, 2012
Macleods Pharmaceuticals, LtdFor profitMKTGAug 15, 2014
MylanFor profitSYNApr 23, 2012
MylanFor profitMKTGApr 23, 2012
Natco PharmaFor profitMKTGApr 23, 2012
NeogenFor profitMKTGAug 15, 2014
NovartisFor profitMKTGOct 24, 2011
Orbion PharmsFor profitMKTGApr 23, 2012
Orchid PharmaFor profitMKTGApr 23, 2012
Par PharmaceuticalsFor profitMKTGOct 24, 2011
Qilu Pharmaceutical Co., Ltd.For profitSYNJan 27, 2016
Qilu Pharmaceutical Co., Ltd.For profitMKTGJan 27, 2016
Roxane LaboratoriesFor profitMKTGSep 29, 2006
SandozFor profitSYNNov 16, 2012
SandozFor profitMKTGOct 24, 2011
SankyoFor profitMKTGMar 20, 2012
Strides Pharma ScienceFor profitMKTGOct 24, 2011
Sun PharmaceuticalsFor profitMKTGFeb 28, 2012
Sunshine Lake Pharma Co., Ltd.For profitMKTGJul 3, 2018
Sunshine Lake Pharma Co., Ltd.For profitMKTGNov 19, 2018
Sunshine Lake Pharma Co., Ltd.For profitSYNNov 19, 2018
TevaFor profitMKTGOct 24, 2011
Torrent Pharmaceuticals LimitedFor profitSYNOct 25, 2011
Torrent Pharmaceuticals LimitedFor profitMKTGApr 23, 2012
Torrent Pharmaceuticals LimitedFor profitSYNOct 25, 2011
Zhejiang Hisun Pharmaceutical Co. Ltd.For profitMKTGDec 31, 2020
Zydus Discovery DMCCFor profitMKTGJul 17, 2018